AnnJi Pharmaceutical überführt AJ201 in die zulassungsrelevante Phase-3-Studie „ROMA-KD" zur Behandlung der spinalen und bulbären Muskelatrophie (SBMA)

Summary

AnnJi Pharmaceutical initiated the Phase 3 ROMA-KD trial for AJ201 (Rosolutamid), an oral small molecule drug targeting spinal and bulbar muscular atrophy (SBMA). AJ201 is described as the only known investigational therapy in Phase 3 clinical development for SBMA.